These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35396773)

  • 1. Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamide-chlorambucil conjugate.
    Funasaki S; Mehanna S; Ma W; Nishizawa H; Kamikubo Y; Sugiyama H; Ikeda S; Motoshima T; Hasumi H; Linehan WM; Schmidt LS; Ricketts C; Suda T; Oike Y; Kamba T; Baba M
    Cancer Sci; 2022 Jul; 113(7):2352-2367. PubMed ID: 35396773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
    Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
    Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.
    Argani P; Hicks J; De Marzo AM; Albadine R; Illei PB; Ladanyi M; Reuter VE; Netto GJ
    Am J Surg Pathol; 2010 Sep; 34(9):1295-303. PubMed ID: 20679884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
    Wei S; Tian F; Xia Q; Huang P; Zhang Y; Xia Z; Wu M; Yang B
    Cancer Imaging; 2019 Dec; 20(1):1. PubMed ID: 31892340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma.
    Liu N; Chen Y; Yang L; Shi Q; Lu Y; Ma W; Han X; Guo H; Li D; Gan W
    Clin Transl Med; 2022 Apr; 12(4):e797. PubMed ID: 35452181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
    Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
    Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
    Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
    Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of immunohistochemistry, FISH and RT-PCR shows high incidence of Xp11 translocation RCC: comparison of three different diagnostic methods.
    Lee HJ; Shin DH; Noh GY; Kim YK; Kim A; Shin N; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Rha SH; Park SW
    Oncotarget; 2017 May; 8(19):30756-30765. PubMed ID: 28415646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
    Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
    Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic Contrast-Enhanced CT Characterization of Xp11.2 Translocation/TFE3 Gene Fusions versus Papillary Renal Cell Carcinomas.
    He J; Zhou K; Zhu B; Zhang G; Li X; Guo H; Gan W; Zhou Z; Liu T
    Biomed Res Int; 2015; 2015():298679. PubMed ID: 26636097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.
    Ellis CL; Eble JN; Subhawong AP; Martignoni G; Zhong M; Ladanyi M; Epstein JI; Netto GJ; Argani P
    Mod Pathol; 2014 Jun; 27(6):875-86. PubMed ID: 24309327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in Saudi adult patients with renal cancer: a retrospective tissue microarray analysis.
    Al-Maghrabi J; Mufti S; Gomaa W
    Pol J Pathol; 2018; 69(4):376-383. PubMed ID: 30786687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.
    Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y
    Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma.
    Kim SH; Choi Y; Jeong HY; Lee K; Chae JY; Moon KC
    Virchows Arch; 2011 Sep; 459(3):299-306. PubMed ID: 21773754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis.
    Klatte T; Streubel B; Wrba F; Remzi M; Krammer B; de Martino M; Waldert M; Marberger M; Susani M; Haitel A
    Am J Clin Pathol; 2012 May; 137(5):761-8. PubMed ID: 22523215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
    Rao Q; Zhou J; Zhang RS; Ma HH; Zhou HB; Lu ZF; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):582-6. PubMed ID: 21092583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis.
    Yang B; Duan H; Cao W; Guo Y; Liu Y; Sun L; Zhang J; Sun Y; Ma Y
    Mod Pathol; 2019 Oct; 32(10):1521-1535. PubMed ID: 31175325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
    Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
    Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRCC-TFE3 dual-fusion FISH assay: A new method for identifying PRCC-TFE3 renal cell carcinoma in paraffin-embedded tissue.
    Xiong L; Chen X; Liu N; Wang Z; Miao B; Gan W; Li D; Guo H
    PLoS One; 2017; 12(9):e0185337. PubMed ID: 28949976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
    Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
    Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.